Invited commentary  by Hiatt, William R.
Your first slide implied the lower the better. We see the cardiolo-
gists going from what used to be levels of 3 mmol/L down to 2 for
LDL to now less than 2. Based on this data, what threshold would
you recommend for trying to get a patient’s LDL cholesterol to?
Dr Bulbulia. There should be no threshold for initiation of
statin therapy. HPS was not a target-finding study, but results from
some “more vs less” statin trials suggest that higher doses of statin
therapy will reduce cardiac and noncardiac vascular events further.
However, the question is whether the risks of side effects associated
with statins, which are dose-dependent, justify this approach.
Dr Jacob Lustgarten (Chevy Chase,Md). Did you notice any
morbidity and mortality benefits in patients who underwent sur-
gery? Statins are increasingly associated with a plaque stabilization
effect and a lower perioperative rate of adverse cardiac events, and
even a lower stroke risk after carotid surgery. It seems almost like
these patients should be on statins much the way -blockers are
used. You followed a large number of randomized patients. Did
you look for this effect?
Dr Bulbulia. We have not performed such an analysis, but I
am aware of the results of observational and smaller interventional
studies suggesting improved outcomes with statin therapy in the
perioperative period. However, our results clearly demonstrate
that all these patients should be on a statin before, during, and after
their operation.
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Current guidelines give a class I recommendation to lower
low-density lipoprotein (LDL) cholesterol levels below 100
mg/dL in all patients with peripheral artery disease (PAD) and a
class IIa recommendation to lower the LDL cholesterol level
below 70 mg/dL in patients who are at “very high risk of ischemic
events.”1 High-risk PAD would be defined as more than one
vascular bed involved—eg, a clinical history of concomitant coro-
nary or cerebral vascular disease. The primary evidence for these
recommendations comes from the original publication of the
Heart Protection Study that evaluated the benefits of simvastatin in
over 20,000 high-risk patients.2 There were 6748 patients with
PAD reported in the original publication, and these patients had a
reduction in fatal and nonfatal cardiovascular events with simvasta-
tin similar to that in patients with other forms of atherosclerosis. A
recent meta-analysis of statin therapy in a broad population of
high-risk patients demonstrated that there was a consistent benefit
in reduction of risk of cardiovascular events across a wide popula-
tion of patients and a wide range of baseline LDL cholesterol
levels.3 Thus there is a broad consensus to treat all patients at risk
with statin drugs, regardless of their baseline cholesterol level.
The publication of the Heart Protection Study Collaborative
Group in the Journal of Vascular Surgery focuses on the benefits of
statin therapy specifically in the PAD population. The major new
finding was a significant reduction in noncoronary revasculariza-
tions. Confirmatory findings were the consistency of the benefit
across all populations studied (including patients with PAD who
had no pre-existing coronary artery disease) and benefit regardless
of baseline LDL cholesterol level. There was no benefit of the statin
in preventing amputations, perhaps reflecting the end-stage patho-
physiology of patients who suffer limb loss.
Themessage is clear. All patients with PAD are at high risk and
meet criteria for statin therapy. The benefit of statin therapy is
primarily systemic (prevention of major cardiovascular events) but
also local (reduction of the need for revascularization).
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